Sipuleucel-T in prostate cancer: Indication of added benefit

Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.

http://ift.tt/1FLjVID